{"product_id":"bsx-bcg-matrix","title":"(BSX) Boston Scientific Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Boston Scientific Corporation BCG Matrix helps you see how the company’s products or business units fit into the Stars, Cash Cows, Question Marks, and Dogs framework. The page already includes a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFARAPULSE PFA, AF ablation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFARAPULSE is Boston Scientific Corporation’s clearest 2025 growth engine in electrophysiology: in Q1 2025, Electrophysiology sales jumped 124% reported to $493 million, driven by pulsed field ablation adoption. The platform is riding a fast-growing AF market, with FARAPULSE now a major launch engine across U.S. and international hospitals. High growth, strong procedure momentum, and expanding installed use fit a Star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWATCHMAN FLX Pro, LAAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWATCHMAN FLX Pro is a Star for Boston Scientific Corporation: it leads the left atrial appendage closure market, where stroke-prevention use is still expanding. In 2025, Boston Scientific kept funding clinical data, physician training, and launches in new markets to widen adoption. The franchise pairs scale, category leadership, and growth in a market where atrial fibrillation affects about 59 million people worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLithoVue, single-use ureteroscope\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLithoVue fits a Stars profile because Boston Scientific Corporation is riding the move to single-use ureteroscopy in urology. The platform has a large installed base and each case drives repeat disposables, so demand stays tied to procedure volume, not just capital sales. That mix points to high share, strong growth, and durable follow-on revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEP mapping and navigation tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEP mapping and navigation tools stay a growth pocket for Boston Scientific because AF ablation demand is rising and FARAPULSE depends on a full workflow, not just a pulse generator. The global AF market is large: about 60 million people live with atrial fibrillation, and ablation use keeps climbing as centers add new energy platforms. This makes mapping and navigation strategically important, even if it is not the biggest sales line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports FARAPULSE adoption\u003c\/li\u003e\n\u003cli\u003eBenefits from AF ablation growth\u003c\/li\u003e\n\u003cli\u003eHigh strategic workflow value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEXALT Model D, single-use duodenoscope\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEXALT Model D fits the \"Star\" slot in Boston Scientific Corporation's BCG Matrix: single-use duodenoscopy directly tackles infection-control and reprocessing risk, and the category is expanding faster than reusable endoscopy hardware. Boston Scientific said the Endoscopy business generated $4.3 billion in 2024 revenue, while single-use devices gain share as hospitals cut scope-reprocessing labor and cross-contamination exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-use duodenoscopy lowers reprocessing risk.\u003c\/li\u003e\n\u003cli\u003eMarket growth outpaces reusable hardware.\u003c\/li\u003e\n\u003cli\u003eBoston Scientific is in a newer, faster-expanding segment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoston Scientific’s Growth Stars Are Driving Big Wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s Stars are FARAPULSE, WATCHMAN FLX Pro, LithoVue, and EP mapping and navigation tools, because each combines high share with fast procedure growth. FARAPULSE drove Electrophysiology sales to $493 million in Q1 2025, up 124% reported. WATCHMAN addresses a 59 million-person AF pool, and Endoscopy revenue reached $4.3 billion in 2024, supporting EXALT Model D and LithoVue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFARAPULSE\u003c\/td\u003e\n\u003ctd\u003eFast adoption\u003c\/td\u003e\n\u003ctd\u003e$493M Q1 2025 EP sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWATCHMAN FLX Pro\u003c\/td\u003e\n\u003ctd\u003eLeader in growth market\u003c\/td\u003e\n\u003ctd\u003e59M AF patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXALT Model D\u003c\/td\u003e\n\u003ctd\u003eSingle-use share gain\u003c\/td\u003e\n\u003ctd\u003e$4.3B Endoscopy revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBoston Scientific’s BCG Matrix maps its devices by growth and share to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG snapshot of Boston Scientific to spot winners, cash cows, and drag areas fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Boston Scientific assumptions, boosting credibility and making decisions easier to verify.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNERGY drug-eluting stents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNERGY drug-eluting stents sit in a mature coronary stent market with slower growth than newer procedural areas, but the franchise still monetizes a large installed base and recurring PCI demand. Boston Scientific keeps getting cash flow from repeat use in a market where coronary revascularization volumes remain high, so this is classic Cash Cow territory. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore endoscopy disposables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s core endoscopy disposables fit Cash Cows because GI endoscopy accessories, biopsy tools, and hemostasis products are repeat-use items tied to procedure volume, not fast market growth. In fiscal 2025, Boston Scientific reported about $19.4 billion in net sales, and its Endoscopy business kept benefiting from steady demand in hospitals and ASCs. That makes these products reliable cash producers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeripheral artery intervention tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeripheral artery intervention tools fit Boston Scientific Corporation’s Cash Cow zone: stents, atherectomy, and related devices serve a mature vascular market, with broad commercial reach and steady replacement demand. The business should keep generating strong operating cash because pricing is stable and sales are less volatile than EP or LAAC. This makes it a dependable funding source for higher-growth franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUrology consumables and access products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUrology consumables and access products are a cash cow for Boston Scientific Corporation because they sell with each procedure, so revenue repeats with case volume. In 2024, Boston Scientific Corporation reported $16.7 billion in net sales, and this mature line needs less launch spend than newer platforms, helping fund higher-growth bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat sales from procedure volume\u003c\/li\u003e\n\u003cli\u003eLower launch spending than new platforms\u003c\/li\u003e\n\u003cli\u003eStrong cash support for growth bets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy rhythm management hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy rhythm management hardware is a cash cow for Boston Scientific Corporation: pacemakers and older ICD\/CRT-D lines are mature, low-growth categories, but they still bring in steady cash from replacement cycles and service support. The upside is limited versus newer franchises, so this bucket is mainly about protecting margin and funding faster-growing areas.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady replacements support cash flow\u003c\/li\u003e\n\u003cli\u003eService revenue adds recurring income\u003c\/li\u003e\n\u003cli\u003eGrowth lags newer Boston Scientific lines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoston Scientific’s Cash Cows Keep the Cash Flowing in 2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s Cash Cows are mature, repeat-use lines like SYNERGY stents, endoscopy disposables, peripheral tools, urology consumables, and legacy rhythm devices. In fiscal 2025, Boston Scientific Corporation reported $19.4 billion in net sales, and these franchises kept producing cash from high procedure volume and replacement demand. They need less launch spend, so they help fund faster-growth areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNERGY stents\u003c\/td\u003e\n\u003ctd\u003eMature PCI market\u003c\/td\u003e\n\u003ctd\u003eSteady repeat demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndoscopy disposables\u003c\/td\u003e\n\u003ctd\u003eProcedure-linked sales\u003c\/td\u003e\n\u003ctd\u003eRecurring hospital use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrology consumables\u003c\/td\u003e\n\u003ctd\u003eUse per case\u003c\/td\u003e\n\u003ctd\u003eLow launch spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eBoston Scientific Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Boston Scientific Corporation BCG Matrix preview is the exact same document you’ll receive after purchase. No placeholders, no watermark—just the full, professionally formatted file. You can use it right away for analysis, planning, or presentation. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy bare-metal coronary stents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy bare-metal coronary stents are a Dogs category for Boston Scientific Corporation: older formats sit in a low-growth market and have been displaced by drug-eluting stents, which now dominate PCI care. This line is a shrinking, low-single-digit share of the portfolio, while newer cardiovascular products drive most growth. Low demand and weak pricing make it a low-return asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder diagnostic EP catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s older diagnostic EP catheters fit the Dog box: in 2025-2026, newer mapping, imaging, and pulsed field ablation (PFA) workflows took the lead, so these legacy tools are no longer the main EP growth driver.\u003c\/p\u003e\n\u003cp\u003eThat shift matters because PFA is scaling fast, while traditional diagnostic catheters face weak relative share and low category growth.\u003c\/p\u003e\n\u003cp\u003eFor Boston Scientific, the smarter capital goes to higher-growth EP platforms, not aging catheter lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConventional CRT-D systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s conventional CRT-D systems sit in a mature, highly competitive heart-failure device market, where global heart failure affects about 64 million people and replacement demand is steadier than new growth. Their legacy CRT-D line lacks the faster expansion seen in Boston Scientific Corporation’s newer rhythm franchises, so it fits a low-growth, low-share profile. In BCG terms, that points closer to a Dog than a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-growth pacemaker variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s standard pacemaker line fits the Dogs bucket because it is a mature, low-growth niche that mostly depends on replacement demand, while newer EP and LAAC products drive the company’s growth. In 2025, Boston Scientific Corporation reported net sales of about $16.7 billion, showing that pacemakers are not the main expansion engine. These units are usually cash-neutral, not a big source of incremental upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature market, slow organic growth\u003c\/li\u003e\n\u003cli\u003eMostly replacement-driven demand\u003c\/li\u003e\n\u003cli\u003eOutpaced by EP and LAAC\u003c\/li\u003e\n\u003cli\u003eCash-neutral, not a growth driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy neuromodulation implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s legacy neuromodulation implants fit a Dog profile: older pain and stimulation systems have been overshadowed by newer platforms and tougher rivals, so growth and pricing power are weak. In 2025, Boston Scientific generated about $16.7 billion in net sales, but this older niche lacks the scale and momentum of the company’s faster-growing categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder systems face weaker differentiation.\u003c\/li\u003e\n\u003cli\u003eNew launches and rivals take share.\u003c\/li\u003e\n\u003cli\u003eGrowth stays limited versus top franchises.\u003c\/li\u003e\n\u003cli\u003eLow momentum supports Dog status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoston Scientific’s Legacy Devices Lag While New Therapies Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation's Dogs are legacy lines in slow or shrinking niches: bare-metal stents, older EP catheters, standard pacemakers, CRT-D, and older neuromodulation. In 2025, net sales were about $16.7 billion, but these units were not the growth engine. Newer platforms like PFA and other advanced therapies took share and capital. They fit low-growth, low-share roles.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog line\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy devices\u003c\/td\u003e\n\u003ctd\u003eLow growth, weak pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 net sales\u003c\/td\u003e\n\u003ctd\u003e$16.7 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAGENT drug-coated balloon\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAGENT is a Question Mark in Boston Scientific Corporation’s BCG matrix: it targets coronary in-stent restenosis, a meaningful but still early market, and the device won U.S. FDA approval in April 2024. That gives Boston Scientific a chance to build share, but adoption is still not proven at scale. The upside is real, yet near-term volume and profit contribution remain uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACURATE neo2 transcatheter valve\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eACURATE neo2 sits in Question Marks: structural heart is still a large, growing market, but Boston Scientific is not yet as dominant here as in EP or LAAC. The valve has strategic option value outside the U.S., where TAVR demand keeps rising and Boston Scientific can still win share. Growth upside is real, but share remains uncertain, so this is a high-potential, high-risk bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeep brain stimulation systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeep brain stimulation systems are a Question Mark for Boston Scientific Corporation: neuromodulation is growing, but DBS is still a 3-horse race against Medtronic and Abbott. In 2025, Boston Scientific had a much larger total sales base, yet DBS needs faster share gains and proof of scale before it deserves heavier capital. The market is attractive, but the ROI case is not proven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVenous thrombectomy and thrombolysis systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVenous thrombectomy and thrombolysis systems sit in a fast-growing but still early category, so Boston Scientific Corporation is more in share-building mode than in harvest mode. The business matters because clot-removal adoption is rising, but it is still far smaller than Boston Scientific Corporation's core franchises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth area, not a core profit engine\u003c\/li\u003e\n\u003cli\u003eAdoption is still uneven\u003c\/li\u003e\n\u003cli\u003eWinning share is the main task\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBoston Scientific Corporation participates, but the platform is still developing relative to its larger cardiovascular and electrophysiology businesses. That makes execution and hospital penetration more important than near-term scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterventional oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInterventional oncology is a Question Mark for Boston Scientific Corporation: embolization and ablation can grow fast, but the unit still lacks clear company-wide share leadership. Boston Scientific’s 2025 focus on selective capital and trial-backed product wins matters, because this space rewards scale and strong clinical data more than broad brand power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, still weak share\u003c\/li\u003e\n\u003cli\u003eBest backed by selective R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eDrift risk if spend is too thin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoston Scientific’s Growth Bets: Early Wins, No Durable Scale Yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBoston Scientific Corporation’s Question Marks are AGENT, ACURATE neo2, deep brain stimulation, venous thrombectomy\/thrombolysis, and interventional oncology. These are growth bets, but none has proven durable scale yet; AGENT’s U.S. FDA approval came in Apr 2024, while the rest still face uneven adoption and share gaps in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAGENT\u003c\/td\u003e\n\u003ctd\u003eFDA Apr 2024\u003c\/td\u003e\n\u003ctd\u003eEarly share build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDBS\u003c\/td\u003e\n\u003ctd\u003e3-way rivalry\u003c\/td\u003e\n\u003ctd\u003eScale not proven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191790051593,"sku":"bsx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bsx-bcg-matrix.webp?v=1783678447","url":"https:\/\/dcfanalyst.com\/products\/bsx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}